000 02405 a2200661 4500
005 20250516100132.0
264 0 _c20121025
008 201210s 0 0 eng d
022 _a1528-0020
024 7 _a10.1182/blood-2012-02-414631
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aVerstovsek, Srdan
245 0 0 _aLong-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls.
_h[electronic resource]
260 _bBlood
_cAug 2012
300 _a1202-9 p.
_bdigital
500 _aPublication Type: Comparative Study; Evaluation Study; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
650 0 4 _aAdult
650 0 4 _aAged
650 0 4 _aAged, 80 and over
650 0 4 _aCase-Control Studies
650 0 4 _aClinical Trials, Phase I as Topic
_xstatistics & numerical data
650 0 4 _aClinical Trials, Phase II as Topic
_xstatistics & numerical data
650 0 4 _aClinical Trials, Phase III as Topic
_xstatistics & numerical data
650 0 4 _aCohort Studies
650 0 4 _aFemale
650 0 4 _aFollow-Up Studies
650 0 4 _aHumans
650 0 4 _aJanus Kinase 1
_xantagonists & inhibitors
650 0 4 _aJanus Kinase 2
_xantagonists & inhibitors
650 0 4 _aMale
650 0 4 _aMiddle Aged
650 0 4 _aNitriles
650 0 4 _aPrimary Myelofibrosis
_xdiagnosis
650 0 4 _aProtein Kinase Inhibitors
_xtherapeutic use
650 0 4 _aPyrazoles
_xtherapeutic use
650 0 4 _aPyrimidines
650 0 4 _aRandomized Controlled Trials as Topic
_xstatistics & numerical data
650 0 4 _aSurvival Analysis
650 0 4 _aSurvivors
_xstatistics & numerical data
650 0 4 _aTreatment Outcome
650 0 4 _aAssessment of Medication Adherence
700 1 _aKantarjian, Hagop M
700 1 _aEstrov, Zeev
700 1 _aCortes, Jorge E
700 1 _aThomas, Deborah A
700 1 _aKadia, Tapan
700 1 _aPierce, Sherry
700 1 _aJabbour, Elias
700 1 _aBorthakur, Gautham
700 1 _aRumi, Elisa
700 1 _aPungolino, Ester
700 1 _aMorra, Enrica
700 1 _aCaramazza, Domenica
700 1 _aCazzola, Mario
700 1 _aPassamonti, Francesco
773 0 _tBlood
_gvol. 120
_gno. 6
_gp. 1202-9
856 4 0 _uhttps://doi.org/10.1182/blood-2012-02-414631
_zAvailable from publisher's website
999 _c21882582
_d21882582